Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
Rhea-AI Summary
Liquidia (NASDAQ:LQDA) will present four posters at the PHA 2026 International PH Conference and Scientific Sessions in Dallas, June 11-14, 2026.
Posters cover ASCENT study data on YUTREPIA in PH-ILD, patient-reported cough, caregiver mental health, pharmacist roles, and an encore of safety and exploratory efficacy data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LQDA
On the day this news was published, LQDA gained 9.77%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.2% during that session. Our momentum scanner triggered 46 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $574M to the company's valuation, bringing the market cap to $6.45B at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Index inclusion | Positive | +4.4% | Announced upcoming addition to the S&P SmallCap 600 Index. |
| May 27 | Conference appearance | Positive | +3.2% | Planned Jefferies conference fireside chat on company business. |
| May 11 | Earnings results | Positive | +25.6% | Reported strong Q1 2026 results driven by YUTREPIA sales. |
| May 06 | Investor conferences | Neutral | +5.0% | Planned participation in two May 2026 investor conferences. |
| May 04 | Earnings date set | Neutral | +0.9% | Scheduled Q1 2026 results release and webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, including index inclusion and earnings, has frequently coincided with positive price reactions.
Over the past months, Liquidia has reported several milestones, including strong Q1 2026 results with notable YUTREPIA contribution on May 11, 2026 and upcoming S&P SmallCap 600® inclusion announced on June 8, 2026. Investor and healthcare conference participation in early May and late May also aligned with positive price moves. Today’s scientific poster announcements at a pulmonary hypertension meeting continue a pattern of active clinical, commercial, and investor engagement built around YUTREPIA and related programs.
Regulatory & Risk Context
An effective Form S-3ASR shelf filed on 2026-03-05 allows Liquidia to offer various securities from time to time, with specific terms detailed in future prospectus supplements. The filing references YUTREPIA commercialization, a Sandoz collaboration, and ongoing litigation over YUTREPIA.
Key Terms
pulmonary hypertension medical
interstitial lung disease medical
treprostinil medical
inhalation powder medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that the company will present four posters at the PHA 2026 International PH Conference and Scientific Sessions taking place June 11-14 in Dallas.
Liquidia will present data from Cohort A of its ASCENT study of YUTREPIA® (treprostinil) inhalation powder, including patient-reported cough outcomes in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) over 24 weeks of treatment. The company will also present new data and analyses examining the role of pharmacists within PH care teams and the mental health burden experienced by caregivers of patients with PH. In addition, Liquidia will present an encore of previously reported safety and exploratory efficacy data from the ASCENT study.
Dr. Rajeev Saggar, Liquidia Chief Medical Officer, said: “We are proud to share our research with the patients and caregivers at the center of the pulmonary hypertension community. From listening to patients describe their own experience with treatment to understanding the burden carried by caregivers and the role of the care teams who support them, this work reflects our commitment to the people living with this condition every day.”
All posters will be presented from 4 to 5 p.m. CDT Thursday, June 11, in the exhibition hall. Upon presentation, each publicly presented poster will be available on the publications page of Liquidia’s website at https://liquidia.com/publications.
New Poster Presentations
Poster #1014
Hearing from Patients: Self-Reported Cough Outcomes During Treatment with YUTREPIA® (treprostinil) in the ASCENT Trial
Poster #1055
The Invisible Burden: Mental Health Challenges Facing Caregivers of Patients with Pulmonary Hypertension
Poster #1072
The PHriendly Neighborhood Pharmacist: Mapping the Pharmacist’s Role in Pulmonary Hypertension Care Teams
Encore Presentation
Poster #1060
A Continued ASCENT to Week 24: Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients
About YUTREPIA® (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Investor Contact:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media Contact:
media@liquidia.com
